Find a Doctor or Practice Location

You can also search for providers and practices at Penn Medicine Lancaster General Health or Princeton Health.

within
I am searching for a
Reset Form
David J. Vaughn, MD

David J. Vaughn, MD Physician

Vice Chief for Clinical Affairs, Hematology/Oncology GU Medical Oncology Professor

Languages spoken:

  • Spanish

Dr. Vaughn is employed by Penn Medicine.

About Dr. David J. Vaughn

Recognized by America's Top Doctors, 2008, 2010, 2011 - 2018

Recognized by Best Doctors in America 2003 - 2018

Recognized in Philadelphia magazine's annual Top Docs issues, 2002, 2008, and 2010 - 2019

Patient Satisfaction Ratings

Patient Rating Breakdown

The Patient Satisfaction Rating is an average of all responses to the care provider related questions shown below from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Overall Ratings

Clinical Specialties

Specialty:

  • Medical Oncology

Programs & Centers:

Board Certification:

  • Medical Oncology, 1993

Clinical Expertise:

  • Active Surveillance of Prostate Cancer
  • Adrenal Neoplasm
  • Biological Targeted Therapy
  • Cancer Chemotherapy
  • Carcinoma In Situ of Prostate
  • Chemoradiation
  • Extragonadal Germ Cell Tumor
  • Immunotherapy
  • Malignancies of the Genitourinary System
  • Malignant Neoplasm of the Ureter
  • Malignant Neoplasm of Ureteric Orifice
  • Malignant Tumor of Male Genital Organ
  • Malignant Tumor of Renal Pelvis
  • Metastatic Prostate Cancer
  • Neoplasm of Epididymis
  • Penile Cancer
  • Scrotal Tumor
  • Seminoma
  • Teratoma
  • Testicular Choriocarcinoma
  • Testicular Tumors
  • Transitional Cell Carcinoma
  • Urachal Cancer
  • Urethral Cancer
Show All Expertise

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Amerihealth Caritas
  • Amerihealth Caritas Medicare
  • Cigna
  • Cigna HealthSpring
  • Clover Health Plan
  • CVS Health
  • Devon Health Services (Americare)
  • eLAP Services
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Homestead Smart Health Plans
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Keystone First Medicare
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Health and Wellness (Centene) Medicare
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Provider Partners Health Plan
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan
  • Veterans Choice Program

Education and Training

Medical School: Harvard University
Residency: NewYork-Presbyterian/Weill Cornell Medical Center
Fellowship: Hospital of the University of Pennsylvania

Memberships

American Board of Internal Medicine, National American College of Physicians, National American Society of Clinical Oncology, National Eastern Cooperative Oncology Group, National

Hospital Affiliation

Dr. Vaughn is employed by Penn Medicine.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: On the medical staff, but does not have privileges to treat patients in the hospital.

Research

Description of Research Expertise:

New Drug Development for Urologic Cancer
Cancer Survivorship

Selected Publications:

Abu Zaid M, Dinh PC, Monahan PO, Fung C, El-Charif O, Feldman DR, Hamilton RJ, Vaughn DJ, Beard CJ, Cook R, Althouse S, Ardeshir-Rouhani-Fard S, Sesso HD, Huddart R, Mushiroda T, Kubo M, Dolan ME, Einhorn LH, Fossa SD, Travis LB; Platinum Study Group: Adverse health outcomes in relationship to hypogonadism after chemotherapy: a multicenter study of testicular cancer survivors. Journal of the National Comprehensive Cancer Network 17 (5): 459-468,2019.

Osterman CK, Babu DS, Geynisman DM, Lewis B, Somer RA, Balar AV, Zibelman MR, Guancial EA, Antinori G, Yu S, Narayan V, Guzzo TJ, Plimack ER, Vaughn DJ, Fung C, Mamtani R: Efficacy of split schedule versus conventional schedule neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer. Oncologist 24 (5): 688-690,2019.

AlDubayan SH, Pyle LC, Gamulin M, Kulis T, Moore ND, Taylor-Weiner A, Hamid AA, Reardon B, Wubbenhorst B, Godse R, Vaughn DJ, Jacobs LA, Meien S, Grgic M, Kastelan Z, Markt SC, Damrauer SM, Rader DJ, Kember RL, Loud JT, Kanetsky PA, Greene MH, Sweeney CJ, Kubisch C, Nathanson KL, Van Allen EM, Stewart DR, Lessel D; Regeneron Genetics Center (RGC) Research Team: Association of inherited pathogenic variants in Checkpoint Kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors. Journal of the American Medical Association Oncology 5 (4): 514-522,2019.

Trendowski MR, El Charif O, Ratain MJ, Monahan P, Mu Z, Wheeler HE, Dinh PC, Feldman DR, ArdeshirRouhaniFard S, Hamilton R, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Hannigan R, Strathmann FG, Einhorn LH, Fossa SD, Travis LB, Dolan ME.: Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy. Clinical Cancer Research : 2019.

El Charif O, Mapes B, Trendowski MR, Wheeler HE, Wing C, Dinh PC Jr, Frisina RD, Feldman DR, Hamilton RJ, Vaughn DJ, Fung C, Kollmannsberger C, Mushiroda T, Kubo M, Gamazon ER, Cox NJ, Huddart R, Ardeshir-Rouhani-Fard S, Monahan P, Fossa SD, Einhorn LH, Travis LB, Dolan ME: Clinical and genome-wide analysis of cisplatin-induced tinnitus implicates novel ototoxic mechanisms. Clinical Cancer Research : 2019.

Feld E, Harton J, Meropol NJ, Adamson BJS, Cohen A, Parikh RB, Galsky MD, Narayan V, Christodouleas J, Vaughn DJ, Hubbard RA, Mamtani R: Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer. European Urology : 2019.

Narayan V, Vaughn DJ, Ky B.: Cardiovascular toxicities of therapy for genitourinary malignancies. Urologic Oncology : 2019.

Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Nam K, Frenkl TL, Perini RF, de Wit R, Bajorin DF: Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Annals of Oncology : 2019.

Vaughn DJ: Testicular cancer Harrison's Principles of Internal Medicine, 20th Edition : 632-637,2018.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Mortazavi A, Vaughn DJ, Isaacs RE, Parker K, Chen X, Yu K, Porter D, Sharma S, Graus Porta D, Bajorin DF: Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discovery 8 (7): 812-21,2018.

Academic Contact Info

Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-114
3400 Civic Center Blvd

Philadelphia, PA 19104-4283
Phone: (215) 349-8140
Patient appointments: 800-789-7366 (PENN)

Related Links